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Familial Melanoma–Associated Mutations in p16
Uncouple its Tumor-Suppressor Functions
Noah C. Jenkins1,2, Jae Jung3, Tong Liu2, Megan Wilde2, Sheri L. Holmen1,2,4 and Douglas Grossman1,2,3
Familial melanoma is associated with point mutations in the cyclin-dependent kinase (CDK) inhibitor p16INK4A
(p16). We recently reported that p16 regulates intracellular oxidative stress in a cell cycle–independent manner.
Here we constructed 12 different familial melanoma–associated point mutants spanning the p16 coding region
and analyzed their capacity to regulate cell cycle phase and suppress reactive oxygen species (ROS). Compared
with wild-type p16, which fully restored both functions in p16-deficient fibroblasts, various p16 mutants differed
in their capacity to normalize ROS and cell cycle profiles. Although some mutations did not impair either
function, others impaired both. Interestingly, several mutations impaired cell cycle (R24Q, R99P, and V126D) or
oxidative functions (A36P, A57V, and P114S) selectively, indicating that these two functions of p16 can be
uncoupled. Similar activities were confirmed with selected mutants in human melanoma cells. Many mutations
impairing both cell cycle and oxidative functions, or only cell cycle function, localize to the third ankyrin repeat of
the p16 molecule. Alternatively, most mutations impairing oxidative but not cell cycle function, or those not
impairing either function, lie outside this region. These results demonstrate that particular familial melanoma–
associated mutations in p16 can selectively compromise these two independent tumor-suppressor functions,
which may be mediated by distinct regions of the protein.
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INTRODUCTION
The cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor
p16INK4a (or p16) is encoded by the chromosomal locus
CDKN2A and altered in most human tumors (Sharpless and
DePinho, 1999). Germline mutations in p16 have been
associated more commonly with a subset of cancers, namely
pancreatic carcinoma and melanoma, and are inherited in
B40% of melanoma-prone families (Goldstein et al., 2007). In
the presence of potentially oncogenic stress such as DNA
damage, the canonical tumor-suppressor function of p16
involves binding either to CDK4/6 or preassembled CDK4/6–
cyclin D complexes (Serrano et al., 1993; Hirai et al., 1995),
inhibiting hyperphosphorylation of retinoblastoma-associated
pocket proteins and delaying cell cycle progression from the
G1 to S phase (Lukas et al., 1995; Alcorta et al., 1996). In this
setting, p16 may induce cellular senescence or allow time for
DNA repair before cell division (Shapiro et al., 1998).
Interestingly, several studies have demonstrated that many
familial melanoma–associated p16 mutants retain CDK4-
binding capacity in vitro (Hashemi et al., 2000; Becker
et al., 2001; Kannengiesser et al., 2009; McKenzie et al.,
2010), suggesting that p16 may mediate an additional
important function(s) independent of cell cycle regulation.
As penetrance of melanoma in p16 mutant kindreds is
highly associated with chronic exposure to UV radiation
(Bishop et al., 2002), which produces reactive oxygen
species (ROS) in the skin (Herrling et al., 2006), we recently
investigated a possible role for p16 in regulating intracellular
oxidative stress. We found increased oxidative stress in cells
depleted of p16 that was independent of cell cycle regulation
(Jenkins et al., 2011). Melanocytes demonstrated increased
susceptibility to oxidative stress in the context of p16
depletion compared with keratinocytes and fibroblasts
(Jenkins et al., 2011). Thus, melanocytes appear to be more
dependent on p16 for normal oxidative regulation than other
cell types, which may in part explain why inherited mutations
in p16 predispose to melanoma over other cancers.
Given this newly identified role of p16 in regulating
intracellular oxidative stress, we investigated whether different
familial melanoma–associated p16 mutations can differen-
tially modulate its cell cycle and oxidative regulatory func-
tions. A panel of p16 mutants was constructed and compared
with wild-type p16 in functional assays using p16 /Arfþ /þ
cells. Interestingly, several mutations selectively compromised
control of cell cycle or oxidative stress, effectively uncoupling
these two functions. Taken together, these data show
that these two potential tumor-suppressor functions of
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p16 can be independently disrupted by distinct familial
melanoma–associated mutations, and different regions of the
protein may be important for these separate functions.
RESULTS
Wild-type p16 suppresses ROS and cell cycle progression, and
induces senescence in p16 /Arfþ /þ cells
Our previous work (Jenkins et al., 2011) demonstrating
sufficiency of p16 in mediating control of intracellular
oxidative stress was performed in fibroblasts deficient in
CDKN2A, which encodes both the p16 and alternative
reading frame (Arf, p19) proteins (Sharpless and DePinho,
1999). We began by confirming these results using cells that
were selectively deficient in p16 (i.e., wild-type for Arf).
Fibroblasts from wild-type mice were infected with control
lentivirus expressing green fluorescent protein (GFP), whereas
p16 /Arfþ /þ fibroblasts were separately infected with either
lentivirus expressing p16 and GFP or GFP alone. We had
previously optimized conditions for viral transduction to
achieve 80–90% infection rates (as measured by GFP visua-
lization using fluorescence microscopy) and expression of
exogenous p16 (by western blotting) roughly equivalent to
p16 levels in wild-type fibroblasts. Infection of p16-deficient
cells with p16 lentivirus resulted in p16 levels comparable to
those observed in wild-type cells (Figure 1a, bottom), and was
associated with the normalization of ROS, whereas ROS levels
were significantly higher in p16-deficient cells infected with
GFP lentivirus (Figure 1a, top). These control (GFP) p16 /
Arf
þ /þ
cells also exhibited a dysregulated cell cycle profile
evidenced by a marked decrease in the proportion of cells in
G1 phase and increase in the proportion in G2/M phase
(Figure 1b). Introduction of p16 expression in p16 /Arfþ /þ
cells normalized the cell cycle distribution, increasing the frac-
tion of cells in G1 phase and decreasing the fraction in G2/M
phase (Figure 1b). These results provide evidence that the
expression of p16 is both necessary and sufficient in
p16 /Arfþ /þ cells to mediate oxidative and cell cycle
regulation.
In some experimental systems, p16 expression was asso-
ciated with both senescence and increased ROS (Takahashi
et al., 2006), whereas in others, increased p16 expression was
not associated with increased ROS (Macip et al., 2002). Thus,
we examined whether reduced ROS associated with the
introduction of p16 into p16 /Arfþ /þ cells was associated
with cellular senescence. The p16 /Arfþ /þ fibroblasts were
separately infected with either lentivirus expressing p16/GFP
or GFP alone, and then assessed for b-galactosidase activity
over a 7-day period. We found that although no senescent
cells were evident in cultures of p16 /Arfþ /þ fibroblasts
infected with control GFP lentivirus, cells infected with p16
lentivirus became increasingly positive for senescence-
associated b-galactosidase (Supplementary Figure S1 online).
Thus, although the relationship between p16 expression and
ROS appears subject to experimental context (Vurusaner et al.,
2012), in our system, restoring p16 expression correlates with
reduced ROS and increased G1 arrest and senescence.
Functional activities of familial melanoma–associated p16
mutants
To investigate the potential functional consequences of
particular mutations in p16 that have been identified in
human melanoma kindreds (Hashemi et al., 2000; Becker
et al., 2001; Kannengiesser et al., 2009; McKenzie et al.,
2010), we prepared lentiviral constructs encoding 12 point
mutants spanning the length of the p16 coding region
(Supplementary Table S1 online). Although nine of the
mutations are predicted to affect only the p16 and not Arf
coding sequences (R24P, R24Q, G35A, G35V, A36P, A57V,
2,500
a b
100
75
50
25
0
2,000
1,500
1,000
D
CF
 fl
uo
re
sc
en
ce
 u
ni
ts
Pe
rc
e
n
t c
om
po
sit
io
n
500
0
WT
WT
***
***
***
**
Cells:
Lenti: GFP GFP
p16–/– p16–/–
p16–/– (GFP)
p16–/– (p16)
p16
G1 S G2M
p16
Arf
Actin
Figure 1. p16 expression normalizes reactive oxygen species (ROS) and cell cycle profile in p16 /Arfþ /þ cells. (a) Wild-type (WT) and p16-deficient
fibroblasts were infected with either green fluorescent protein (GFP; control) lentivirus or lentivirus expressing wild-type p16 as indicated. After 72 hours, cell
lysates were subjected to DCFDA (2,7-dichlorodihydrofluorescein diacetate) assay for intracellular ROS (upper panel) and western blotting for p16, alternative
reading frame (Arf), or actin (lower panel). Error bars indicate SEM from triplicate determinations, **Pp0.01. (b) After 72 hours, cell cycle analysis was performed
with percentages of cells in each phase (G1, S, and G2M) indicated. Error bars indicate SEM from triplicate determinations, ***Pp0.001.
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L97R, R99P, and V126D), the remaining three mutations are
predicted to affect both p16 and Arf (P81T, R87W, and
P114S). Each mutant was separately expressed in p16 /
Arf
þ /þ
fibroblasts, and the levels of ROS and cell cycle
distribution were determined and compared with that of cells
expressing either GFP or wild-type p16. Please refer to Table 1
for a guide to the functional grouping of these mutants and the
relevant figures where the data can be found. We defined
‘‘loss-of-function’’ mutants as those demonstrating o30%
restoration of function compared with the wild-type protein,
as defined previously by others (Kannengiesser et al., 2009).
Using this criterion, we found that several p16 mutants
exhibited an impaired capacity to regulate both oxidative
stress and the cell cycle. For example, ROS levels and cell
cycle distribution remained dysregulated in cells expressing
the P81T mutant compared with wild-type p16 (Figure 2a). A
similar phenotype was observed with the L97R (Figure 2b) and
R87W (Figure 2c) mutants. Thus, 3 of the 12 mutants could be
categorized as ‘‘double loss of function’’ (Figure 3).
Interestingly, several p16 mutants largely restored regulation
of both oxidative stress and cell cycle distribution. For
example, the expression of the G35A mutant resulted in
ROS levels and cell cycle distribution that was more compar-
able to that of cells expressing wild-type p16 than GFP
(Figure 2d, Supplementary Figure S3 online). A similar
phenotype was observed for the R24P (Supplementary Figure
S2 online) and G35V (Supplementary Figure S3 online)
mutants. In some cases, because the replicates were very
close, we achieved statistically significant differences between
mutant and wild type with respect to cell cycle parameters,
although the mutant’s activity clearly resembled wild type
more than GFP. This was the case with the A57V mutant
(Figure 2a), as well as G35A (Figure 2d, Supplementary Figure
S3 online), R24P (Supplementary Figure S2 online), and G35V
(Supplementary Figure S3 online). The identification of these
three mutants (none of which affect Arf), which largely retain
both oxidative and cell cycle regulatory functions (Figure 3),
suggests that some mutations in p16 may affect melanoma
predisposition by disrupting other (yet undefined) functional
activities.
Uncoupling of cell cycle and oxidative regulatory functions
For the remaining six p16 mutants, we found that the oxidative
or cell cycle regulatory activity was selectively compromised.
For example, the A57V mutant normalized cell cycle distribu-
tion comparable to wild-type p16, but did not correct elevated
ROS levels (Figure 2a). Similarly, the A36P (Figure 2b) and
P114S mutants (Figure 2c) demonstrated selective loss of
oxidative regulatory function compared with cell cycle reg-
ulatory function. The inverse result was observed with the
R99P mutant, which effectively suppressed ROS levels
but did not restore cell cycle distribution (Figure 2d and
Supplementary Figure S4 online). Similarly, the selective loss
of cell cycle regulatory function compared with oxidative
regulatory function was observed in the V126D (Supple-
mentary Figure S2 online) and R24Q (Supplementary Figure
S4 online) mutants. Thus, the identification of these six
mutants, in which the oxidative and cell cycle regulatory
functions are relatively uncoupled (Figure 3), supports our
previous contention that p16 regulates oxidative stress in a cell
cycle–independent manner (Jenkins et al., 2011).
p16 mutants with altered functional activities retain appropriate
subcellular localization
It is thought that p16 localizes to the nucleus to exert its CDK-
inhibitory function (Lukas et al., 1995; Bartkova et al., 1996),
although exogenous overexpression of p16 can lead to protein
aggregation in the cytoplasm and loss of function (Tevelev
et al., 1996). It has also been suggested that cytoplasmic
localization of p16 may represent a specific mechanism
of its inactivation in tumors (Evangelou et al., 2004). To
demonstrate that alterations in functional activities of some
p16 mutants were not because of protein mislocalization, we
assessed their subcellular localization in p16 /Arfþ /þ
fibroblasts by immunofluorescence. First, we confirmed that
wild-type p16 was strongly nuclear, and no cytosolic
expression was detected (Supplementary Figure S5 online).
Analysis of the 12 different point mutants consistently showed
similar nuclear localization (Supplementary Figure S5 online),
suggesting that their various altered functional activities could
not be attributed to p16 mislocalization.
Analysis of p16 regulatory functions in human melanoma cells
Next, we examined a subset of these mutants in human
melanoma cells—perhaps a more relevant model for analyz-
ing p16 mutations associated with familial melanoma.
WM793 cells, which do not express p16, were transduced
with lentivirus expressing either GFP, wild-type p16, or a
selected p16 mutant. As above, we optimized the expression
of individual mutants to be comparable to expression levels of
wild-type p16 (Figure 4a and b). As observed in p16-deficient
mouse fibroblasts (Figure 1), the expression of wild-type p16
was associated with both ROS suppression (Figure 4c and d)
and cell cycle shift (Figure 4e and f). Mirroring the phenotypes
Table 1. Guide to functional activities of p16 mutants
Category Mutants Figures
Both functions impaired
P81T Figure 2a
L97R Figure 2b
R87W Figure 2c
Both functions retained
G35A Figure 2d, Supplementary Figure S3 online
R24P Supplementary Figure S2 online
G35V Supplementary Figure S3 online
Uncoupling of functions
A57V Figure 2a
A36P Figure 2b
P114S Figure 2c
R99P Figure 2d, Supplementary Figure S4 online
V126D Supplementary Figure S2 online
R24Q Supplementary Figure S4 online
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seen above (Figure 2c and d), the R99P mutant retained
oxidative but not cell cycle function, whereas the P114S
mutant exhibited the reciprocal phenotype (Figure 4c and e)
in WM793 cells. Compared with wild-type p16, the R24Q
mutant was unable to restore significant oxidative (Figure 4d)
or cell cycle function (Figure 4f), consistent with earlier
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Figure 2. Functional activities of familial melanoma–associated p16 mutants. p16-deficient fibroblasts were infected with the indicated lentiviral constructs
expressing green fluorescent protein (GFP), wild-type p16, or (a) mutants P81T or A57V, (b) mutants A36P or L97R, (c) mutants R87W or P114S, or (d) mutants
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*Pp0.05, **Pp0.01, and ***Pp0.001. NS, not significant.
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findings (Supplementary Figure S4 online). Finally, as seen
above (Supplementary Figure S3 online), the G35V mutant
retained cell cycle function comparable to wild-type p16
(Figure 4f), and exhibited intermediate capacity for reducing
ROS (Figure 4d). Importantly, the differential capacity of three
p16 mutants (R99P, P114S, and G35V) to regulate oxidative
versus cell cycle regulatory functions was recapitulated in
human melanoma cells.
Structure–function relationships among p16 mutants
Finally, we examined relative localization of these muta-
tions on the basis of published structures of the molecule
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(Byeon et al., 1998; Russo et al., 1998). p16 consists mainly
of four ankyrin repeats, a conserved motif involved in
various protein–protein interactions (Li et al., 2006).
Although some studies have implicated all four ankyrin
repeats as important for CDK4/6-binding and cell cycle
inhibition, others indicate that the third ankyrin repeat
(residues 81–113) as well as the b-hairpin loop within the
second ankyrin repeat (residues 52–54) are the most critical
regions for mediating these functions (Byeon et al., 1998;
Russo et al., 1998; Mahajan et al., 2007). Consistent with
this notion, several residues that we found to be important
for both cell cycle and oxidative regulation (P81, R87, and
L97), or only cell cycle regulation (R99), reside in the third
ankyrin repeat (Supplementary Figure S6 online). In con-
trast, most residues important for oxidative but not cell cycle
regulation (A36, A57, and P114), or those not important for
either function (G35, R24), are not found within the third
ankyrin repeat or the b-hairpin loop of the second ankyrin
repeat (Supplementary Figure S6 online).
DISCUSSION
We recently described a role for p16 in suppressing intracel-
lular oxidative stress, functioning independently of cell cycle
and its control of the retinoblastoma pathway (Jenkins et al.,
2011). These two regulatory functions are likely to be
complementary in preventing potentially oncogenic
oxidative DNA lesions by decreasing their formation
(reduction of ROS) and propagation (induction of cell cycle
arrest to allow DNA repair). In this study, we examined
separately the cell cycle and oxidative regulatory capacities
of a panel of familial melanoma–associated p16 point
mutants. In half of these mutants, one of these two activities
was selectively compromised (Figure 3). These findings pro-
vide further evidence that p16 regulates intracellular oxidative
stress independently of the cell cycle.
Historically, the cell cycle regulatory function of familial
p16 mutants was assessed by measuring CDK4 binding—as
p16 binding to CDK4/6 is the critical step leading to the
reduction in retinoblastoma phosphorylation and inhibition of
the G1/S transition (Lukas et al., 1995; Alcorta et al., 1996).
The two primary assays used were based on yeast two-hybrid
(Yang et al., 1995) and immunoprecipitation (Hashemi et al.,
2000; Becker et al., 2001; Kannengiesser et al., 2009),
which have been problematic for two reasons. First, several
mutants retained the capacity to bind CDK4, yet were greatly
reduced in capacity for cell cycle regulation (Koh et al., 1995;
Becker et al., 2001). These discrepancies could reflect the
additional known capacity of p16 to bind CDK6 and intact
CDK4/6–cyclin D complexes in addition to CDK4 (Serrano
et al., 1993; Hirai et al., 1995), neither of which was
measured in past studies. Differences in functional assays
may also relate to the potential ability of p16 to bind and
inhibit CDK7, a kinase subunit of the TFIIH transcription
factor (Serizawa, 1998), which may allow induction of cell
cycle arrest independently of CDK4/6 binding (Nishiwaki
et al., 2000). In addition to lack of correlation between
CDK4-binding and cell cycle inhibitory functions found
in some cases, other studies have reported differences in
CDK4-binding activity for the same p16 mutant. For example,
the reported CDK4-binding activity of the G101W mutant
ranged from 5 to 73% of wild type, based on yeast two-hybrid
(Reymond and Brent, 1995; Yang et al., 1995) and
immunoprecipitation assays (Ranade et al., 1995; Walker
et al., 1995; Parry and Peters, 1996; Becker et al., 2001). A
mammalian two-hybrid assay has also been used to measure
interactions between p16 mutants and CDK4 in human
osteosarcoma (Saos-2) cells (McKenzie et al., 2010).
Although mammalian cells allow for posttranslational modifi-
cations, there could be important differences between these
tumor cells and melanocytes or melanoma cells. Rather
than developing our own assay based on CDK4–, CDK6–, or
CDK4/6–cyclin D binding, we wanted to avoid these pitfalls
and directly measure cell cycle regulatory activity; thus, we
determined cell cycle distribution by flow cytometry (which
was highly reproducible) as a readout of the cell cycle
regulatory function of these p16 mutants.
Several previous studies have characterized the effects of
p16 point mutations on cell cycle regulatory activity, yielding
a wide range of phenotypes among different mutants and
conflicting results concerning the same mutants. Some dis-
crepancies may lie in the different assays and cell types used
for assessing cell cycle function, which included the ability to
induce phase arrest (Koh et al., 1995; Becker et al., 2001,
2005; McKenzie et al., 2010; Miller et al., 2011), limit cell
numbers in culture (Jones et al., 2007; Kannengiesser et al.,
2009), reduce proliferation by Ki67/BrdU staining (Jones et al.,
2007; McKenzie et al., 2010), and reduce colony formation
(Becker et al., 2005; Jones et al., 2007) in fibroblasts,
osteosarcoma, and melanoma cells. For the mutants studied
here, however, our results largely agreed with that reported in
the literature. For example, our observations that cell cycle
function was retained (R24P, G35A, and G35V) or only
partially diminished (A36P, A57V, and P114S) in these
particular mutants is consistent with prior reports (Jones
et al., 2007; Kannengiesser et al., 2009; McKenzie et al.,
2010). Similarly, our findings that cell cycle function was
largely diminished (V126D) or completely absent (R99P,
R87W, and L97R) in other mutants is consistent with
previous studies (Becker et al., 2001; Kannengiesser et al.,
2009; McKenzie et al., 2010; Miller et al., 2011). On the other
hand, the lack of cell cycle regulatory function that we
observed for mutants R24Q and P81T was not consistent
with earlier studies, in which the R24Q (Kannengiesser et al.,
2009) and P81T (McKenzie et al., 2010) mutants were found
to be comparable to wild-type p16. For the R24Q mutant, we
confirmed lack of cell cycle function in WM793 human
melanoma cells (Figure 4f). As suggested above, one explana-
tion for these discrepancies in addition to the different assays
is the use of different cell types. The capacity of some mutants
to regulate cell cycle may be unmasked in particular cellular
contexts depending on the different interactions of p16 (i.e.,
with various CDKs) that could be affected. In addition, some
cell lines may be less susceptible to regulation by exogenous
p16 because of the presence of background mutations, or loss
of the entire CDKN2A locus with corresponding lack of
dependency on p16 or ARF.
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It has been reported that the third ankyrin repeat of p16
(residues 81–113) and a b-hairpin loop in the second ankyrin
repeat (residues 52–54) are the most important regions for
CDK4 binding (Fahraeus et al., 1996; Byeon et al., 1998;
Li et al., 1999; Mahajan et al., 2007). Our results further
confirm the importance of this region in p16 for cell cycle
regulation, as the R99P mutant, which demonstrates the most
marked loss of cell cycle function while retaining oxidative
function (Figure 3), is located in the third ankyrin repeat
(Supplementary Figure S6 online). This region forms both an
extensive hydrogen bond network at the interface of CDK4/6
(involving residues 74, 84, and 87 of p16) and a mostly
hydrophobic structural core that interacts with the other
internal helices that may help stabilize the protein (Russo
et al., 1998). Perhaps several mutations in this region upset
either the hydrogen bond network of the binding interface or
these internal stabilizing helices, as most mutants that fail to
restore both cell cycle and oxidative regulatory function
(P81T, R87W, and L97R) are located here (Supplementary
Figure S6 online). Consistent with this notion, the mutants that
failed to impair either function (R24P, G35A, and G35V), or
that selectively impaired oxidative regulation (A36P, A57V,
and P114S), are located outside of this region. These residues
may be involved in direct or indirect interactions with yet
uncharacterized binding partners of p16, or mutations of these
residues could alter the secondary structure of the p16
molecule that precludes interactions required for oxidative
regulatory function. The potential effects of particular muta-
tions studied here on p16 structure are difficult to predict
without analysis of crystal structures of the mutant p16
molecules.
The identification of several familial melanoma–associated
mutants, which largely retain both regulatory functions
(Figure 3), suggests that some p16 mutations may affect
melanoma predisposition by disrupting some other yet-to-be-
defined tumor-suppressor function. There is precedent for
other well-studied tumor-suppressor genes that appear to
regulate ROS independently of their canonical functions
(Vurusaner et al., 2012). For example, p53 is a regulator of
ROS as several p53-target genes include redox-active proteins
and ROS-generating enzymes (Polyak et al., 1997; Macip
et al., 2003), and many posttranslational modifications of p53
generate ROS (Bragado et al., 2007). Another example is the
CDK inhibitor p21 that regulates oxidative stress by increasing
stability of Nrf2, allowing increased Nrf2-mediated
transactivation of several antioxidant enzymes (Chen et al.,
2009). Finally, the breast cancer susceptibility genes BRCA1
and BRCA2 also appear to be involved in regulating oxidative
stress. BRCA1 upregulates multiple antioxidant genes,
including glutathione S-transferases and oxidoreductases
(Bae et al., 2004), and both BRCA1 and BRCA2 are required
for the repair of the oxidative DNA lesion 8-oxoguanine
(Le Page et al., 2000). The elucidation of noncanonical roles
of p16 as well as other tumor suppressors in the regulation of
cellular oxidative stress may signal the development of a new
paradigm in which tumor-suppressor proteins use multiple
mechanisms that may be disabled in cancer, or in patients
with cancer predisposition syndromes.
MATERIALS AND METHODS
Cell culture
Murine fibroblasts were isolated from newborn wild-type (FVB)
and background-matched p16 /Arfþ /þ (#01XE4, FVB.129-
Cdkn2atm2.1Rdp) homozygous mice (Kamijo et al., 1997), both
obtained from the National Cancer Institute (Rockville, MD), as we
have previously described (Jenkins et al., 2011). These procedures
were approved by the Institutional Animal Care and Use Committee
of the University of Utah. Early passage cells (B2 weeks after
isolation) were aliquotted and stored at  80 1C. For each set of
experiments, fresh cells were thawed and used over a 2–3-week
period. WM793 melanoma cells were originally obtained from
Meenhard Herlyn (Wistar Institute, Philadelphia, PA).
Western blotting
Specific proteins were detected in cell lysates by western blotting as
previously described (Jenkins et al., 2011). Primary antibodies were
used against p16 (1:1,000; SC-1661, Santa Cruz Biotechnology, Santa
Cruz, CA), b-actin (1:10,000, A-3853; Sigma-Aldrich, St Louis, MO),
and ARF (1:1,000, sc-22784; Santa Cruz Biotechnology).
Measurement of oxidative stress
Endogenous ROS of protein equivalents (30mg) were quantified using
2,7-dichlorodihydrofluorescein diacetate (DCFDA; Life Technologies,
Grand Island, NY) as previously described (Jenkins et al., 2011). All
experiments were conducted in triplicate.
p16-expressing lentiviruses
The lentivirus expressing human wild-type p16 is previously
described (Jenkins et al., 2011). The p16 point mutant constructs
were generated by PCR-based segment overlap as described
previously (Raj et al., 2008), using human p16 complementary
DNA as a template and primers designed to create specific point
mutations. In brief, an initial PCR reaction was used to separately
create the 50 and 30 fragments for each mutant. The 50 fragment was
constructed using wild-type p16 sequence as ‘‘primer 1’’ and mutant
sequence as ‘‘primer 2,’’ and the 30 fragment was constructed using
wild-type p16 sequence as ‘‘primer 2’’ and mutant sequence as
‘‘primer 1’’ (Supplementary Table S1 online). A second PCR reaction
was then used to anneal these individual segments, using equimolar
amounts of the 50 and 30 fragments as template and primers
corresponding to wild-type p16. The final PCR product was cloned
into a modified pHIV-Zsgreen (Addgene 18121, Cambridge, MA)
lentiviral expression vector (Welm et al., 2008) and confirmed by
DNA sequencing. Each lentiviral construct was validated for p16
expression by transient transfection into HeLa cells followed by
western blotting. Viruses were produced in HEK 293T/17 cells
(ATCC, Manassas, VA) cotransfected with 5mg lentiviral vector and
1.7mg of each helper plasmid (pRSV-REV, pMDLg/pRRE, and pVSVG,
generously provided by Brian Welm, Huntsman Cancer Institute, Salt
Lake City, UT) and 30mg of polyethylenimine (pH 7.0, Sigma, St
Louis, MO) in 1 ml of OptiMEM (Life Technologies). Viral particles
were collected, purified, concentrated, titered, and stored as
described previously (Jenkins et al., 2011). For cellular infection,
8mg per ml polybrene (Sigma) was added. Assays for oxidative stress
and cell cycle distribution in WM793 cells were performed 16 and
48 hours after infection, respectively, and after 72 hours in fibroblasts.
Experiments involving each mutant were conducted at least twice.
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Cell cycle analysis
Cells were harvested by trypsinization, washed, fixed, stained with
50 mg per ml propidium iodide (Sigma), and analyzed as described
previously (Jenkins et al., 2011). All experiments were conducted in
triplicate.
Senescence-associated b-galactosidase staining
Staining was performed as described previously (Cotter et al., 2007). In
brief, cells were fixed in 1% paraformaldehyde and then stained
overnight at 37 1C in a solution (pH 6.0) containing potassium ferro-
cyanide, potassium ferricyanide, and 5-bromo-4-chloro-3-indolyl-b-D-
galactoside (X-gal). All experiments were conducted in triplicate.
Immunofluorescence
Cultured fibroblasts were seeded on coverslips in 12-well plates at
30–40% confluency, transduced by lentivirus, and then fixed 72 hours
after infection with PBS containing 4% paraformaldehyde for 15 min-
utes. Cells were permeabilized with 0.2% Triton X-100 in PBS, and
then immunostained for 60 minutes with anti-p16 (1:1,000, sc-1661;
Santa Cruz Biotechnology), followed by a 60-minute exposure to
Alexa Fluor 594–conjugated secondary IgG (1:200, A-11062; Life
Technologies). Images were captured on a Zeiss Axioskop2 automated
microscope, using an Axio Cam MRm camera and AxioVision 4.8.1
software (Carl Zeiss Microscopy, Thornwood, NY), and then processed
using ImageJ software (http://rsbweb.nih.gov/ij/download.html).
Structural analysis
Structural modeling of p16 was performed using SwissPdb Viewer
(http://www.expasy.org/spdbv) as described elsewhere (Guex and
Peitsch, 1997), based on the p16 published structure 1a5e (Byeon
et al., 1998).
Statistics
Analyses were performed using Prism 3.0 software (GraphPad,
La Jolla, CA). Data derived from multiple determinations were
subjected to two-sided t-tests. The P-values of p0.05 were consid-
ered statistically significant. Statistical significance is denoted within
each figure as *Pp0.05, **Pp0.01, and ***Pp0.001.
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